Gastric and Gastroesophageal Junction Adenocarcinoma - Current and Future Players

Home/Gastric and Gastroesophageal Junction Adenocarcinoma - Current and Future Players

Gastric and Gastroesophageal Junction Adenocarcinoma - Current and Future Players

Regulation & Policy (Pharma & Healthcare), Finance & Investment (Pharma & Healthcare), Deals & Alliances (Pharma & Healthcare), Pharma & Healthcare

Publication ID:

GDA1215625

Publication Date:

December 09, 2015

Pages:

122

Publisher:

GlobalData

Region:

Global

$2,995.00

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

Gastric and Gastroesophageal Junction Adenocarcinoma - Current and Future Players

Summary

GlobalData has released its pharma report, “Gastric and Gastroesophageal Junction Adenocarcinoma - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Gastric and Gastroesophageal Junction Adenocarcinoma (G/GEJAC) Market. The report identifies and analyses the key companies shaping and driving the global G/GEJAC market. The report provides insight into the competitive G/GEJAC landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Investigation of current and future market competition for G/GEJAC
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of G/GEJAC sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving G/GEJAC market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global G/GEJAC market landscape? Identify, understand and capitalize

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Market Outlook
3.1 Global Markets
3.1.1 Forecast
3.1.2 Drivers and Barriers - Global Issues
4 Current and Future Players
4.1 Overview
4.2 Trends in Corporate Strategy
4.3 Company Profiles
4.3.1 Bristol-Myers Squibb
4.3.2 Eli Lilly and Company
4.3.3 Merck & Co.
4.3.4 Roche
4.3.5 Taiho Pharmaceutical
4.3.6 Sumitomo Dainippon Pharma
5 Appendix
5.1 Bibliography
5.2 Abbreviations
5.3 Methodology
5.4 Forecasting Methodology
5.4.1 Hospitalized MRSA Patients
5.4.2 Percentage of Drug-Treated MRSA Patients
5.4.3 Drugs Included in Each Therapeutic Class
5.4.4 Launch, Label Expansion, and Patent Expiry Dates
5.4.5 General Pricing Assumptions
5.4.6 Individual Drug Assumptions
5.4.7 Generic Erosion
5.4.8 Pricing of Pipeline Agents
5.5 Primary Research - KOLs Interviewed for This Report
5.6 Primary Research - Prescriber Survey
5.7 About the Authors
5.7.1 Author and Therapy Area Director
5.7.2 Author
5.7.3 Epidemiologist
5.7.4 Global Director of Therapy Analysis and Epidemiology
5.7.5 Global Head of Healthcare
5.8 About GlobalData
5.9 Disclaimer

1.1 List of Tables
Table 1: Global Sales Forecast ($m) for G/GEJAC, 2014-2024
Table 2: G/GEJAC Market - Drivers and Barriers, 2015
Table 3: Key Companies in the G/GEJAC Market in the 8MM, 2014-2024
Table 4: BMS’ G/GEJAC Portfolio Assessment, 2015
Table 5: Eli Lilly’s G/GEJAC Portfolio Assessment, 2015
Table 6: Merck & Co.’s G/GEJAC Portfolio Assessment, 2015
Table 7: Roche’s G/GEJAC Portfolio Assessment, 2015
Table 8: Taiho’s G/GEJAC Portfolio Assessment, 2015
Table 9: SDP’s G/GEJAC Portfolio Assessment, 2015
Table 10: Key Historical and Projected Launch Dates for MRSA Across the 7MM
Table 11: Key Historical and Projected Label Expansion Dates for MRSA Across the 7MM
Table 12: Key Historical and Projected Patent Expiry Dates for MRSA Across the 7MM
Table 13: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

1.2 List of Figures
Figure 1: Global Sales for G/GEJAC by Region, 2014-2024
Figure 2: Global Sales of Branded Products for G/GEJAC by Company, 2014-2024
Figure 3: Company Portfolio Gap Analysis in G/GEJAC, 2014-2024
Figure 4: Bristol-Myers Squibb SWOT Analysis in G/GEJAC, 2014-2024
Figure 5: Eli Lilly SWOT Analysis in G/GEJAC, 2014-2024
Figure 6: Roche SWOT Analysis in G/GEJAC, 2014-2024
Figure 7: Taiho SWOT Analysis in G/GEJAC, 2014-2024
Figure 8: Sumitomo Dainippon SWOT Analysis in G/GEJAC, 2014-2024

Companies Covered

Bristol-Myers Squibb
Eli Lilly and Company
Merck & Co.
Roche
Taiho Pharmaceutical
Sumitomo Dainippon Pharma

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?

If yes, then please use the form given below and we will get in touch with you immediately.

Kindly use your official email address and contact number to ensure speedy response.

Name *

Email *

Company

Contact Number *

Report Title *

Your Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drag or click the correct shape to the grey "drop area".